RPG Life Sciences Reports Mixed Performance in Q2 2024-25, Highest Operating Cash Flow and Sales Recorded
RPG Life Sciences, a smallcap pharmaceutical company, has reported a flat performance in the second quarter of fiscal year 2024-25. However, the company's operating cash flow and net sales have shown positive growth. On the other hand, the profit after tax and earnings per share have declined. MarketsMojo has advised investors to hold their positions in the company's stock.
RPG Life Sciences, a smallcap pharmaceutical company, recently declared its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.
According to the financial report, RPG Life Sciences has seen a flat performance in the second quarter of the fiscal year 2024-25. The company's score has fallen from 14 to 4 in the last three months.
However, there are some positive aspects to the company's financials. The operating cash flow for the year has been the highest at Rs 94.36 crore and has grown consistently over the last three years. The net sales for the quarter were also the highest at Rs 172.21 crore in the last five quarters, indicating a positive trend in sales. The operating profit (PBDIT) for the quarter was also the highest at Rs 45.93 crore, with a positive trend in the near term. The operating profit margin has also improved, reaching its highest at 26.67%.
On the other hand, there are some areas of concern for RPG Life Sciences. The profit after tax (PAT) for the quarter has fallen by -48.9% compared to the average of the previous four quarters. The earnings per share (EPS) for the quarter were also the lowest at Rs 2.54, indicating a decline in profitability and lower earnings for shareholders.
Overall, RPG Life Sciences has shown a mixed performance in the second quarter of the fiscal year 2024-25. Investors are advised to hold their positions in the company's stock, as recommended by MarketsMOJO.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
